Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ ... a good chance they will recover and still deliver strong returns to patient investors. But which one is likely to perform better than the ...

although there is a good chance they will recover and still deliver strong returns to patient investors. But which one is likely to perform better than the other? Let's find out. Novo Nordisk has ...

The deal extends an agreement to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease ...

In response, according to Reuters, Sanofi said that its patient assistance programmes limit out-of-pocket expenses to $15 per month for the majority of insured patients, while Novo Nordisk ...

Welcome to Arts Spotlight, highlighting arts- and community-based organizations and their programs and projects funded by the ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.